Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

View:
Post by MyBuddyy on Mar 28, 2021 3:43pm

Patent

I did find a provisional patent in the US that hasn't been granted yet.    I'm just trying to figure out if SaNOtize and R107 would fight for patent areas or if they can exist together.     SaNOtize patent was granted in 2014
Comment by Votan2015 on Mar 28, 2021 3:47pm
The dont need to fight as the 2 compounds are different. We have a R-107 wideworld patent and Sanotize has own patent I guess. We only share that both compounds are administered by a spray. 
Comment by MyBuddyy on Mar 28, 2021 3:55pm
Votan.  I don't agree.  The patent office takes issue with "similarities" or "confusion" in which they'll reject the patent of the company with less right to it.   SaNOtize bejng first is my biggest concern. 
Comment by Votan2015 on Mar 28, 2021 3:59pm
Man, the 2 different compunds. No point to worry.
Comment by Votan2015 on Mar 28, 2021 4:00pm
And our has been already patented. 
Comment by MyBuddyy on Mar 28, 2021 4:06pm
Oh they're not both Nitric Oxide ?
Comment by mavericks2020 on Mar 28, 2021 4:11pm
R-107 four choice to take it
Comment by indaknownewfie on Mar 28, 2021 10:14pm
Both are Nitric Oxide based, however their patented makeup is different. Sanotize uses acidified NO that mixes together . R-107 when introduced  into the body works with the body's own NO production centers to maximize a sustained delivery of NO over a period of days. So the delivery methods are the same, but scientific composition and method of action are different. 
Comment by mavericks2020 on Mar 28, 2021 3:48pm
but KLY have four mthod to give the R-107 Unlike nitric oxide, which is a gas that must be administered by a trained respiratory therapists using special delivery equipment, R-107 is a liquid that can be easily administered orally in a capsule, or nasally though use of a nasal spray, or by a single intramuscular injection. Due to its ease of administration, R-107 is designed to overcome the ...more  
Comment by MyBuddyy on Mar 28, 2021 3:53pm
Agreed except my issue is with the SaNOtize patent which covers the nasal.   (Which would be the popular one) 
Comment by Votan2015 on Mar 28, 2021 3:54pm
Our nasal version can also be popular.
Comment by mavericks2020 on Mar 28, 2021 3:56pm
but whit R-107 you have four choice
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities